Published in final edited form as:

Carbohydr Res. 2008 July 21; 343(10-11): 1693–1706. doi:10.1016/j.carres.2008.03.037.

Synthesis of spacer-equipped di-, tri-, and the tetrasaccharide fragments of the deacetylated O-PS1 of *Citrobacter gillenii* O9a, 9b, and a related pentasaccharide

Rina Saksena, Anatoli Chernyak, and Pavol Kováč*

NIDDK, LBC, National Institutes of Health, Bethesda, MD 20892-0815 (U.S.A.)

Abstract

The title rhamnooligosaccharides [α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-1-*O*-(CH₂)₅COOMe, α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-1-*O*-(CH₂)₅COOMe, α -D-Rhap4NAc-(1 $\rightarrow$ 2)- α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-1-*O*-(CH₂)₅COOMe, and α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-(1 $\rightarrow$ 2)- α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-1-*O*-(CH₂)₅COOMe] were synthesized in a stepwise fashion from 5-methoxycarbonylpentyl 4-azido-4,6-dideoxy-2-*O*-benzyl- α -D-mannopyranoside and orthogonally protected 1-thioglycoside glycosyl donors. The amorphous, final products were fully characterized as corresponding per-*O*-acetyl derivatives.

1. Introduction

Citrobacter gillenii O9a,9b is one of *Citrobacter* strains that are found in the intestinal tract of some vertebrates, and may be associated with meningitis, brain abscesses, and neonatal sepsis in humans.¹ A characteristic feature² of *C. gillenii* O9a,9b is the presence of two different O-polysaccharides (PS) as parts of the lipopolysaccharide (LPS). One of them (PS2) is a homopolymer composed of α -(1 $\rightarrow$ 2)-linked 4-acetamido-4,6-dideoxy- α -D-mannopyranose (*N*-acetyl-D-perosamine, D-Rhap4NAc) residues. The other one (PS1) is also built up of *N*-acetyl-D-perosamine, and its tetrasaccharide repeating unit has the structure: $\rightarrow$ 3)- α -D-Rhap4NAc-(1 $\rightarrow$ 2)- α -D-Rhap4NAc-(1 $\rightarrow$ 2)- α -D-Rhap4NAc-(1 $\rightarrow$ 3)- α -D-Rhap4NAc-(1 $\rightarrow$). The NMR data suggest² that the O-PS1 is partially 2-*O*-acetylated, and that the degree of acetylation of the $\rightarrow$ 3-linked *N*-acetyl-D-perosamine residues is ~70%. Gel-permeation chromatography of products of mild acid hydrolysis of the *C. gillenii* O9a,9b LPS yielded PS1 and PS2 in 11.4 and 18% yield, respectively.

Rabbit antiserum raised against *C. gillenii* O9a,9b bacteria reacted with PS1 in Ouchterlony double immunodiffusion test and immunoblotting. PS2 and LPS from *Vibrio cholerae* O:1, which has a structurally related O-PS, were not reactive with the same sera. It was reasoned² that the unreactivity was due to the small molecular size of PS2, and to the different *N*-acetyl group present in the O-PS from *V. cholerae* O:1. The structure of the tetrasaccharide repeating unit of PS1 lacking the *O*-acetyl group is the same as the tetrasaccharide part of a pentasaccharide repeating unit from the O-chain PS of *Escherichia hermannii*,³ the bacteria

*Corresponding Author. Tel.: 301-496-3569; fax: 301-496-1685; e-mail: kpn@helix.nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

often isolated from infected wounds. It is noteworthy, in this context, that the serological reactivity of the LPS of *C. gillenii* O9a,9b was not affected by O-deacetylation.²

2. Results and Discussion

This laboratory has been involved in developing a conjugate vaccine for cholera using synthetic fragments of the O-PS of *V. cholerae* O:1 as the antigenic component.^{4–8,9} The considerable structural similarity between the O-PS of *V. cholerae* O:1 and *C. gillenii* O9a,9b lies in the presence of the (1→2)- α -linked D-perosamine in both O-PSs. The two polysaccharides differ in the N-acyl groups present, i.e., acetyl in *C. gillenii* O9a,9b as compared to 3-deoxy-L-glycerotetronyl group in *V. cholerae* O:1, and in absence of the (1→3)-interglycosidic linkages and O-acetyl groups in *V. cholerae* O:1. The usefulness of pure, well defined fragments of the O-PS of *C. gillenii* O9a,9b as probes for inhibition studies and studies of cross-reactivity as well as our experience in the chemical synthesis of perosamine-containing oligosaccharides^{10–15} prompted us to synthesize fragments that mimic partial structures of the O-PS of *C. gillenii* O9a,9b.

Because O-acetyl groups are not present in the O-PS of *V. cholerae* O:1, and their presence in the O-PS of *C. gillenii* O9a,9b was found non-essential for serology,² we designed the synthetic schemes to yield non-acetylated oligosaccharides (Scheme 1–Scheme 4). To obtain the tetrasaccharide repeating unit and the two oligosaccharide fragments from which it is formed, we chose a stepwise synthetic strategy starting with the linker (spacer)-equipped glycosyl acceptor **12**. In this way, as the linker chosen can be readily transformed into derivatives suitable for conjugation, the final oligosaccharides were obtained in form amenable to both inhibition/binding studies and preparation of neoglycoconjugates by a variety of protocols.^{16–18}

The hitherto unknown compound **12** was obtained from mesylate **1**¹⁹ following a series of known conversions where a number of minor modifications led to improved yields of desired intermediates and/or made the individual steps experimentally less demanding. Consequently, the known^{20,21} azido compound **2** was prepared by combining advantages of each of the previous two protocols leading to it.^{20,21} We used mesylate **1**, recommended by Eis and Ganem²⁰ but prepared by an improved procedure,¹⁹ and treated it with NaN₃²⁰ in the presence of a crown ether, as used by Bundle et al.²¹ with methyl 6-deoxy-1,2-O-isopropylidene-4-O-trifluoromethanesulfonyl- α -D-mannopyranoside. In this way, we were able to readily introduce the azido function while bypassing the need to use of the better, trifluoromethanesulfonyloxy leaving group,²¹ which would be cost prohibitive when working on a large scale. Unlike with the conversion in the absence of the crown ether, only slight discoloration of the reaction mixture occurred during the displacement reaction, and the crystalline azide **2** was obtained consistently in 80–90% yield.

Precursors to glycosyl donors bearing selectively removable protecting groups at position O-2 or O-3, benzyl ethers **3** and **4**, which were required for the synthesis of oligosaccharides containing (1→2)- and (1→3)-linkages, were obtained by selective benzylation of **2** by phase transfer catalysis and benzylation via stannylation, respectively. The reaction time of the phase-transfer mediated alkylation could be shortened, and the yield of the conversion²² **2**→**3** + **4** could be improved by using a larger relative amount of the phase-transfer catalyst. The mixture was resolved by column chromatography, and the 2-benzyl ether was now obtained crystalline. Some amount of the 3-benzyl ether **4** was obtained from this reaction but the bulk of this compound was obtained by benzylation of the 2,3-stannylene acetal of **2**. However, instead of applying the original procedure²⁰ leading to **4**, which required removal of large amount of unchanged BnBr, we employed the benzylation protocol by Nashed²³ (c.f. Experimental). Acetolysis of **3** gave the hitherto unknown 1,3-di-O-acetyl derivatives **5** (α) and **6** (β). The 1,3-

di-*O*-acetyl derivative **5** and its 1,2-*O*-acetylated analog **7**, prepared as described,^{14,21} were subsequently transformed to the corresponding 1-thioglycosides **8** and **10**,^{14,21} respectively. The β anomer **9**, formed when **5** was treated with ethanethiol and isolated by chromatography along with **8**, was also fully characterized.

	R	R ¹	R ²	R ³	R ⁴
1	H	OMe	H	H	OMs
2	H	OMe	H	H	N ₃
3	H	OMe	Bn	H	N ₃
4	H	OMe	H	Bn	N ₃
5	H	OAc	Bn	Ac	N ₃
6	OAc	H	Bn	Ac	N ₃
7	H	OAc	Ac	Bn	N ₃
8	H	SEt	Bn	Ac	N ₃
9	SEt	H	Bn	Ac	N ₃
10	H	SEt	Ac	Bn	N ₃
11	H		Bn	Ac	N ₃
12	H		Bn	H	N ₃

5-Methoxycarbonylpentyl glycoside **12** was prepared from acetate **11** by Zemplén deacetylation. The latter was obtained from **6** and 5-methoxycarbonylpentanol²⁴ by SnCl₄-mediated²⁵ glycosylation, essentially as described for preparation of the similar 3-*O*-benzyl derivative.⁷ It is worth noting that the conversion **6**→**11** was fast and afforded a high yield (~80%) of the 1,2-*trans* glycoside, even though the reaction could not involve the acetoxonium ion intermediate, which was the case in previous situations involving a participating group at *O*-2.^{7,25}

Oligosaccharides **16**, **21** and **26** were synthesized (Scheme 1–Scheme 3) by NIS and silver triflate-mediated condensations of thioglycoside donors **8** or **10**^{14,21} with acceptors **12**, **14** and **19**. The products thus obtained (**13**, **18** and **23**) were deacetylated (Zemplén), to afford glycosyl acceptors (**14**, **19** and **24**) for further extension of the oligosaccharide chain. It is noteworthy that the fast-atom-bombardment (FAB) mass-spectrum of compound **13** showed a peak at *m/z* 685.4, instead of the expected peak at *m/z* 710 ([M + H]⁺). It reflected reduction of one azido group to an amino group during the course of mass-spectrometric analysis.²⁶ The same phenomenon was observed with all compounds containing more than one azido group.

While the one-pot conversion of a single azide group to the *N*-acetamido group by catalytic hydrogenolysis in the presence of Ac₂O and MeOH works well,²⁷ similar conversions described here with compounds containing multiple azido groups were achieved more cleanly using a two step process. The azido groups in **14**, **19**, and **24** were first reduced with H₂S in aqueous pyridine,^{21,28} and subsequent *N*-acetylation with acetic anhydride in presence of methanol gave the acetamido derivatives **15**, **20** and **25**. Catalytic hydrogenolysis of the foregoing substances then gave the target oligosaccharide fragments **16**, **21** and **26**.

The purpose of making the related pentasaccharide **31** was its use in inhibition and other immunochemical studies with antibodies specific for the O-PS of *C. gillenii* O9a,9b. It was obtained by coupling of donor **8** with tetrasaccharide acceptor **24**, to give fully protected pentasaccharide **28**, followed by conversions (Scheme 4) similar to those described above.

The molecular mass of the deprotected oligosaccharides was verified by mass spectrometry and their structures follows from the mode of synthesis. The compounds were fully

characterized as per-O-acetates **17**, **22**, **27** and **32** whose NMR data were fully consistent with their structures.

3. Experimental

3.1 General methods

Unless stated otherwise, optical rotations were measured at ambient temperature for solutions in chloroform ($c \sim 1$), with a Perkin-Elmer automatic polarimeter, Model 341 or with a Jasco automatic polarimeter, Model P-2000. All reactions were monitored by thin-layer chromatography (TLC) on Silica gel 60 coated glass slides (Whatman or Analtech). Column chromatography was performed by gradient elution from columns of silica gel. Solvent mixtures less polar than those used for TLC were used at the onset of development. NMR spectra of monosaccharide derivatives were measured at 22 °C, at 300 MHz (^1H) and 75 MHz (^{13}C), with a Varian Mercury spectrometer. NMR spectra of oligosaccharides were measured at 300 or 600 MHz (^1H) and 75 or 150 MHz (^{13}C), with a Varian Mercury or Bruker Avance spectrometers. All assignments were supported by homonuclear and heteronuclear 2-dimensional correlation spectroscopy, run with the software supplied with the spectrometers. When reporting assignments of NMR signals of oligosaccharides, sugar residues in oligosaccharides are serially numbered, beginning with the one bearing the aglycon, and are identified by a Roman numeral superscript in listings of signal assignments. When reporting NMR data, the nuclei belonging to the spacer aglycon are denoted with a prime ('). ^1H NMR spectra of some compounds containing NHAc groups showed presence of isomers and/or considerable broadening of signals, and coupling constants in such cases are not reported. When presence of isomers was evident, only resonances characteristic of the more abundant isomer are reported. Liquid Chromatography-Electron Spray-Ionization Mass Spectrometry (ESI-MS) was performed with a Hewlett-Packard 1100 MSD spectrometer. Attempts have been made to obtain correct analytical data for all new compounds. However, some compounds tenaciously retained traces of solvents, despite exhaustive drying, and analytical figures for carbon could not be obtained within $\pm 0.4\%$. The $[\alpha]_D$ values reported for such materials may not be quite accurate. Structures of these compounds follow unequivocally from the mode of synthesis and m/z values found in their mass spectra, and TLC and NMR spectroscopy verified their purity. Palladium-on-charcoal catalyst (5%, ESCAT 103) was a product of Engelhard Industries. 1,2-Di-*O*-acetyl-4-azido-3-*O*-benzyl-4,6-dideoxy- α -D-mannopyranoside (**7**) was prepared as described.²¹ Before final freeze-drying of the deprotected oligosaccharides **16**, **21**, **26**, and **31**, their solutions in water (HPLC quality) were passed through the Anotop syringe filter (Whatman, 0.2 μm porosity). Solutions in organic solvents other than alcohols were dried with anhydrous Na_2SO_4 , and concentrated at $<40^\circ\text{C}/2\text{ kPa}$.

3.2 General procedure for the NIS/AgOTf-mediated glycosylations

A mixture of glycosyl donor (1.3 mmol), acceptor (1 mmol) and finely powdered 4 Å molecular sieves (0.5 g) in CH_2Cl_2 (10–15 mL) was stirred under argon for 15 min. The mixture was cooled to $\sim 10^\circ\text{C}$, and solid NIS (1.4 mmol) was added, followed by a solution of AgOTf (0.4 mmol) in toluene (4 mL). The stirring was continued for 3 min at the same temperature, cooling was terminated, and when TLC showed that the reaction was complete (~ 15 min) the mixture was neutralized with Et_3N , partitioned between CH_2Cl_2 and aqueous sodium hydrogen carbonate, concentrated, and the residue was purified by chromatography.

3.4 Methyl 4-azido-4,6-dideoxy- α -D-mannopyranoside (**2**)

A mixture of methyl 4-*O*-methanesulfonyl-6-deoxy- α -D-mannopyranoside¹⁹ (**1**, 142.2 g, 0.555 mol), NaN_3 (87 g, 1.338 mol), and dicyclohexano-15-crown-5 (3.7 g, 16.8 mmol) in DMF (1 L) was heated with vigorous stirring at 100°C until TLC (3:1 hexane–acetone) showed that all starting material was consumed. DMF was evaporated from the yellow reaction mixture,

the residue was treated with CH_2Cl_2 , and the mixture was filtered through a Celite pad. The filtrate was concentrated and the residue was purified by chromatography to give, after crystallization from isopropyl ether–hexane, 95.5 g (85%) of pure **2**, mp. 84–85 °C, ref.²⁰, mp 83–84 °C, 72% yield. CIMS m/z 221 $[\text{M} + \text{NH}_4]^+$.

3.5 Methyl 4-azido-2-*O*-benzyl-4,6-dideoxy- α -D-mannopyranoside (**3**) and methyl 4-azido-3-*O*-benzyl-4,6-dideoxy- α -D-mannopyranoside (**4**)

3.5.1—A mixture of **2** (20 g, 98.4 mmol) and Bu_4NBr (2.7 g, 8.375 mmol), CH_2Cl_2 (300 mL), aqueous 20% NaOH (300 mL) and BnBr (12 mL, 98.4 mmol) was vigorously stirred overnight, when TLC (3:1 hexane–EtOAc) showed almost complete conversion of the starting material. The phases were separated, the aqueous phase was extracted with CH_2Cl_2 , and the combined organic phase was washed with water and concentrated. Chromatography gave first methyl 4-azido-2,3-di-*O*-benzyl-4,6-dideoxy- α -D-mannopyranoside (2.95 g, 7.8%), $[\alpha]_{\text{D}} +60.4$ (*c* 0.9), ref.²² $[\alpha]_{\text{D}} +65.9$ (*c* 2.5). CIMS: m/z 401 $[\text{M} + \text{NH}_4]^+$.

Eluted next was the 2-*O*-benzyl derivative **3** (18.97 g, 65%), mp 35–36 °C (from hexane), $[\alpha]_{\text{D}} +6.4$ (*c* 0.7), ref.,²² $[\alpha]_{\text{D}} +8.54$ (*c* 5.2), for amorphous **3** obtained in 56% yield. CIMS: m/z 311 $[\text{M} + \text{NH}_4]^+$. Anal. Calcd for $\text{C}_{14}\text{H}_{19}\text{N}_3\text{O}_4$: C, 57.33; H, 6.53; N 14.33. Found: C, 57.08; H, 6.46; N, 14.36.

Eluted last was the 3-*O*-benzyl derivative **4**, (4.75 g, 16.5%), CIMS: m/z 311 $[\text{M} + \text{NH}_4]^+$. ^1H NMR data recorded for **3** and **4** agreed with those reported.^{20–22}

3.5.2— Bu_2SnO (40.0 g, 164.7 mmol) was added to a solution of **2** (33 g, 162.4 mmol) in MeOH (~1 L) and the mixture was heated under reflux until a clear solution was obtained (~1–2 h). Toluene (~100 mL) was added and solvents were evaporated. After the residue had been dried in a vacuum oven at 40 °C for 2 h, it was dissolved in DMF (200 mL), benzyl bromide (38 mL, 317 mmol) and Bu_4NI (1 g) was added, and the mixture was heated at ~100 °C until TLC showed complete disappearance of the starting material (4–6 h). After concentration, excess of BnBr was evaporated at 60 °C/133 Pa, and the residue was purified by chromatography to give the desired compound **4** as a light-yellow thick oil (40 g, 84%), which was identical with the material described above.

3.6 1,3-Di-*O*-acetyl-4-azido-2-*O*-benzyl-4,6-dideoxy- α - (**5**) and β -D-mannopyranose (**6**)

A solution of **3** (19.86 g, 67.7 mmol) in Ac_2O – AcOH – H_2SO_4 (50:20:0.01, 480 mL) was kept at room temperature for 45 min, when TLC (40:1 toluene–acetone) showed that the reaction was complete. NaOAc trihydrate was added, to neutralize H_2SO_4 , and the pH was adjusted to ~7 with aqueous Na_2CO_3 and NaHCO_3 . The mixture was extracted with dichloromethane to give, after concentration, crystalline residue **5** (23 g, 93%), mp 60–62 °C (from ethanol), $[\alpha]_{\text{D}} +49.5$ (*c* 0.7). ^1H NMR (300 MHz, CDCl_3): δ 6.12 (d, 1 H, $J_{1,2} = 2.0$ Hz, H-1), 5.05 (dd, 1 H, $J_{2,3} = 3.2$, $J_{3,4} = 10.4$ Hz, H-3), 4.73, 4.55 (2 d, 1 H each, $^2J = 12.5$ Hz, CH_2Ph), 3.81 (dd, 1 H, H-2), 3.74–3.63 (m, 2 H, H-4,5), 2.11, 2.06 (2 s, 3 H each, 2 COCH_3), 1.36 (d, 3 H, $J_{5,6} = 6.0$ Hz, H-6). ^{13}C NMR (75 MHz, CDCl_3): δ 90.93 (C-1), 73.41 (C-2), 72.90 (CH_2Ph), 71.85 (C-3), 69.44 (C-5), 62.04 (C-4), 20.95, 20.77 (2 COCH_3), 18.39 (C-6). CIMS: m/z 381 $[\text{M} + \text{NH}_4]^+$. Anal. Calcd for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_6$: C, 56.19; H, 5.83; N, 11.56. Found: C, 56.43; H, 5.82; N, 11.62.

The mother liquor was purified by chromatography, to give first 400 mg of the α -anomer **5**, total yield, 95%.

Eluted next was a small amount of material that was identified by NMR spectroscopy as the β -anomer **6**, $[\alpha]_{\text{D}} -12.7$ (*c*, 5.1). ^1H NMR (300 MHz, CDCl_3): δ 5.65 (d, 1 H, $J_{1,2} = 0.9$ Hz,

H-1), 4.83, 4.65 (2 d, partially overlapped, $^2J = 12.2$ Hz, CH_2Ph), 4.78 (dd, partially overlapped, $J_{2,3} = 3.2$, $J_{3,4} = 10.5$ Hz, H-3), 4.01 (bd, 1-H, H-2), 3.64 (t, $J = 10.0$ Hz, H-4), 3.44–3.34 (m, 1H, H-5), 2.11, 2.00 (2 s, 3 H each, 2 COCH_3), 1.40 (d, 3 H, $J_{5,6} = 6.0$ Hz, H-6). ^{13}C NMR (75 MHz, CDCl_3): δ 92.14 (C-1), 74.94 (CH_2Ph), 74.32 (C-3), 73.91 (C-2), 71.84 (C-5), 61.81 (C-4), 20.79, 20.63 (2 COCH_3), 18.20 (C-6).

3.7 Ethyl 3-O-acetyl-4-azido-2-O-benzyl-4,6-dideoxy-1-thio- α - (8) and β -D-mannopyranoside (9)

Ethanethiol (7.8 mL, 105 mmol) followed by $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (10.3 mL, 83.7 mmol) was added to a solution of **5**^{14,21} (30 g, 82.6 mmol) in dry CH_2Cl_2 (660 mL), which had been stirred with molecular sieves (4Å, 3 g) for 15 min. The stirring was continued for 20 min at room temperature, when TLC (10:1 hexane–EtOAc) showed that the reaction was complete. After neutralization with aqueous sodium hydrogen carbonate, the product was extracted with CH_2Cl_2 , the organic layer was washed with water and concentrated. The residue was purified by chromatography to give first the α -anomer **8** (25 g), $[\alpha]_{\text{D}} +123$ (c 1.6). ^1H NMR (300 MHz, CDCl_3): δ 5.30 (d, 1 H, $J_{1,2} = 1.2$ Hz, H-1), 5.04 (dd, 1 H, $J_{2,3} = 3.3$, $J_{3,4} = 10.3$ Hz, H-3), 4.71, 4.54 (2 d, 1 H each, $^2J = 12.3$ Hz, CH_2Ph), 4.04–3.96 (m, 2 H, H-2,5), 3.68 (t, 1 H, $J = 10.2$ Hz, H-4), 2.70–2.51 (m, 2 H, CH_2CH_3), 2.07 (s, 3 H, COCH_3), 1.37 (d, 3 H, $J_{5,6} = 6.2$ Hz, H-6), 1.27 (t, 3 H, $J = 7.3$ Hz, CH_2CH_3). ^{13}C NMR (75 MHz, CDCl_3): δ 81.53 ($J_{\text{C-1,H-1}} = 164.2$ Hz, C-1), 76.34 (C-2), 72.71 (C-3), 72.49 (CH_2Ph), 67.22 (C-5), 62.84 (C-4), 25.22 (CH_2CH_3), 20.78 (COCH_3), 18.25 (C-6), 14.74 (CH_2CH_3). CIMS: m/z 383 $[\text{M} + \text{NH}_4]^+$. Anal. Calcd for $\text{C}_{17}\text{H}_{23}\text{N}_3\text{O}_4\text{S}$: C, 55.87; H, 6.34; N, 11.50; S, 8.77. Found: C, 55.99; H, 6.23; N, 11.54; S, 8.75.

Eluted later was the β -anomer **9** (2.2 g), $[\alpha]_{\text{D}} -95$ (c 1.6). ^1H NMR (300 MHz, CDCl_3): δ 4.79 (dd, partially overlapped, $J_{2,3} = 3.2$, $J_{3,4} = 10.4$ Hz, H-3), 4.80, 4.62 (2 d, partially overlapped, $^2J \sim 12.0$ Hz, CH_2Ph), 4.60 (d, partially overlapped, $J_{1,2} \sim 1.0$ Hz, H-1), 4.03 (dd, 1 H, H-2), 3.65 (t, 1 H, H-4), 3.31–3.22 (m, 1 H, H-5), 2.71 (q, 2 H, $J = 7.4$ Hz, CH_2CH_3), 1.98 (s, 3 H, COCH_3), 1.40 (d, 3 H, $J_{5,6} = 6.0$ Hz, H-6), 1.29 (t, 3 H, $J = 7.5$ Hz, CH_2CH_3). ^{13}C NMR (75 MHz, CDCl_3): δ 84.31 ($J_{\text{C-1,H-1}} = 150.6$ Hz, C-1), 77.41 (C-2), 76.18 (C-3), 76.08 (CH_2Ph), 75.65 (C-5), 62.60 (C-4), 27.00 (CH_2CH_3), 21.03 (COCH_3), 18.95 (C-6), 15.34 (CH_2CH_3). CIMS: m/z 383 $[\text{M} + \text{NH}_4]^+$. Anal. Calcd for $\text{C}_{17}\text{H}_{23}\text{N}_3\text{O}_4\text{S}$: C, 55.87; H, 6.34; N, 11.50; S, 8.77. Found: C, 56.17; H, 6.26; N, 11.52; S, 8.76.

The intermediate, mixed fraction (1.85 g) was purified by chromatography, to give more **8** (665 mg, total yield, 85%) and **9** (625 mg, total yield, 9.4%).

3.8 5-Methoxycarbonylpentyl 4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (12)

SnCl_4 (3.5 mL, 29.5 mmol) was added to a solution of **5** (8.25 g, 22.7 mmol) in dry CH_2Cl_2 (200 mL) and the mixture was stirred for 20 min with exclusion of atmospheric moisture. A solution of 5-(methoxycarbonyl)pentanol²⁴ (4.3 g, 29.5 mmol) in dry CH_2Cl_2 (30 mL) was added to a slightly yellow reaction mixture and, when the reaction was complete (~40 min, TLC in 40:1 toluene–acetone), the mixture was neutralized with aqueous, saturated sodium hydrogen carbonate. The product was extracted with CH_2Cl_2 and, after concentration, chromatography gave 5-methoxycarbonylpentyl 3-O-acetyl-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (**11**, 8.28 g, 80%). ^1H NMR (300 MHz, CDCl_3): δ 5.09 (dd, 1 H, $J_{2,3} = 3.3$, $J_{3,4} = 10.3$ Hz, H-3), 4.73 (d, 1 H, $J_{1,2} = 1.8$ Hz, H-1), 4.66, 4.57 (2 d, 1 H each, $^2J = 12.1$ Hz, CH_2Ph), 3.80 (dd, 1 H, H-2), 3.67 (s, partially overlapped, COOCH_3), 3.67–3.43 (m, partially overlapped, H-4,5,1'a), 3.37–3.34 (2 t, 1 H, $J = 6.5$ Hz, H-1'b), 2.31 (t, 2 H, $J = 7.3$ Hz, H-5'a,b), 2.07 (s, 3 H, COCH_3), 1.71–1.51 (m, 4 H, H-4'a,b,2'a,b), 1.39–1.31 (m, 5 H, H-3'a,b, incl. d, 1.35, $J_{5,6} \sim 5.8$ Hz, H-6). ^{13}C NMR (75 MHz, CDCl_3): δ 97.57 ($J_{\text{C-1,H-1}} = 169.1$ Hz, C-1), 75.00 (C-2), 73.14 (CH_2Ph), 72.53 (C-3), 67.53 (C-1'), 66.82 (C-5), 62.74 (C-4),

51.43 (COOCH₃), 33.84 (C-5'), 28.92 (C-2'), 25.58 (C-3'), 24.57 (C-4'), 20.89 (COCH₃), 18.38 (C-6). FABMS: m/z 450 [M + H]⁺, 472 [M + Na]⁺.

A solution of the foregoing acetylated compound **11** (5.66 g, 15.58 mmol) in MeOH (150 mL) was treated with 1 M NaOMe (~5 mL). After 18 h, TLC (5:1 hexane–EtOAc) showed that the deacetylation of **12** was complete. The solution was neutralized with Amberlite IR-120 (H⁺) cation-exchange resin, concentrated, and chromatography of the residue gave **12** (4.38 g, 85%), [α]_D +19.4 (c 4). ¹H NMR (300 MHz, CDCl₃): δ 4.80 (d, 1 H, $J_{1,2}$ = 1.5 Hz, H-1), 4.73, 4.57 (2 d, 1 H each, 2J = 11.7 Hz, CH₂Ph), 3.84 (ddd, 1 H, $J_{2,3}$ = 3.7, $J_{3,4}$ = 10.1 Hz, H-3), 3.67 (dd, partially overlapped, 1 H, H-2), 3.66 (s, partially overlapped, COOCH₃), 3.63, 3.60 (2 t, partially overlapped, J = 6.8 Hz, H-1'a), 3.53–3.44 (m, 1 H, H-5), 3.36, 3.33 (2 t, 1 H, H-1'b), 3.26 (t, 1 H, J = 9.9 Hz, H-4), 2.60 (d, 1 H, $J_{3,OH}$ = 10.3 Hz, OH), 2.30 (t, 2 H, J = 7.4 Hz, H-5' a,b), 1.68–1.50 (m, 4 H, H-4'a,b,2'a,b), 1.39–1.26 (m, 5 H, H-3'a,b, incl. d, 1.31, $J_{5,6}$ = 6.2 Hz, H-6). ¹³C NMR (75 MHz, CDCl₃): δ 96.53 (C-1), 77.36 (C-2), 72.84 (CH₂Ph), 70.22 (C-3), 67.28 (C-1'), 66.39 (2 C, C-4,5), 51.36 (COOCH₃), 33.73 (C-5'), 28.85 (C-2'), 25.51 (C-3'), 24.47 (C-4'), 18.24 (C-6). FABMS: m/z 408 [M + H]⁺, 430 [M + Na]⁺. Anal. Calcd for C₂₀H₂₉N₃O₆: C, 58.95; H, 7.17; N, 10.31. Found: C, 59.10; H, 7.19; N, 10.23.

3.9 5-Methoxycarbonylpentyl (3-O-acetyl-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (**13**)

The glycosyl donor **8** (7.18 g, 19.65 mmol) and the acceptor **12** (6.16 g, 15.12 mmol) were coupled as described in General procedure, to give after chromatography (10:1 $\rightarrow$ 5:1 hexane–EtOAc) **13** (9.385 g, 89%), [α]_D +65 (c 0.8). ¹H NMR (300 MHz, C₆D₆): δ 5.63 (dd, 1 H, $J_{2,3}$ = 3.2, $J_{3,4}$ = 10.0 Hz, H-3^{II}), 5.28 (d, 1 H, $J_{1,2}$ = 1.7 Hz, H-1^{II}), 4.81 (d, 1 H, $J_{1,2}$ = 1.7 Hz, H-1^I), 4.61, 4.48 (2 dd, 1 H each, 2J = 11.8 and 12.1 Hz, 2 CH₂Ph), 4.22 (dd, 1 H, H-2^{II}), 4.14 (dd, 1 H, $J_{2,3}$ = 3.2, $J_{3,4}$ = 9.8 Hz, H-3^I), ~3.87 (m, partially overlapped, H-5^{II}), 3.81 (t, partially overlapped, H-4^{II}), 3.76 (dd, 1 H, H-2^I), 3.71–3.55 (m, 2 H, H-4^I,5^I), 3.47, 3.44 (2 t, 1 H, J = 6.4 Hz, H-1'a), 3.38 (s, 3 H, COOCH₃), 3.13, 3.09 (2 t, 1 H, H-1'b), 2.06 (t, 2 H, J = 7.4 Hz, H-5'), 1.74 (s, 3 H, COCH₃), 1.52–1.42 (m, 2 H, H-4'a,b), 1.35–1.09 (m, 10 H, H-2'a,b,3'a,b, incl. 2 d at 1.24, 1.22, $J_{5,6}$ = 6.1 Hz, H-6^{I,II}). ¹³C NMR (75 MHz, C₆D₆): δ 100.34 (C-1^{II}), 97.88 (C-1^I), 78.39 (C-3^I), 78.15 (C-2^I), 76.25 (C-2^{II}), 73.72, 73.43 (2 CH₂Ph), 72.85 (C-3^{II}), 68.64 (C-5^{II}), 68.20 (C-5^I), 68.05 (C-1'), 65.53 (C-4^I), 63.55 (C-4^{II}), 51.38 (COOCH₃), 34.20 (C-5'), 29.60 (C-2'), 26.25 (C-3'), 25.19 (C-4'), 20.79 (COCH₃), 18.97 (C-6^I), 18.84 (C-6^{II}). FABMS: m/z 685.4 [M + H – 2 N + 2 H]⁺, 843.3 [M + Cs]⁺, 717.1 [M + Li]⁺. Anal. Calcd for C₃₅H₄₆N₆O₁₀: C, 59.14; H, 6.52; N, 11.82. Found: C, 58.95; H, 6.52; N, 11.72.

3.10 5-Methoxycarbonylpentyl (4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (**14**)

De-O-acetylation (Zemplén) of **13** and chromatography (15:1 toluene–EtOAc) gave **14** (4.23 g, 94%), [α]_D +54 (c 1.2). ¹H NMR (C₆D₆, 300 MHz): δ 5.22 (d, 1 H, $J_{1,2}$ = 1.8 Hz, H-1^{II}), 4.81 (d, 1 H, $J_{1,2}$ = 1.8 Hz, H-1^I), 4.50, 4.40 (2 dd, 2 H each, 2J = 11.9 Hz, 2 CH₂Ph), 4.12 (dd, partially overlapped, 1 H, $J_{3,4}$ = 3.1, $J_{2,3}$ = 9.7 Hz, H-3^I), ~4.11 (ddd, partially overlapped, H-3^{II}), 3.90 (dd, 1 H, H-2^{II}), 3.81–3.75 (m, partially overlapped, H-2^I,5^{II}), 3.72 (t, partially overlapped, J = 9.7 Hz, H-4^I), 3.66–3.56 (m, 1 H, H-5^I), 3.34 (t, partially overlapped, J = 9.9 Hz, H-4^{II}), 3.48, 3.45 (2 t, 1 H, J = 6.2 Hz, H-1'a), 3.37 (s, 3 H, COOCH₃), 3.12, 3.09 (2 t, 1 H, H-1'b), 2.17 (d, 1 H, $J_{3,OH}$ = 10.1 Hz, OH), 2.06 (t, 2 H, J = 7.4 Hz, H-5'a,b), 1.52–1.42 (m, 2 H, H-4'a,b), 1.37–1.09 (m, 10 H, H-2'a,b, 3'a,b, incl. 2 d at 1.28, 1.23, $J_{5,6}$ = 6.2 Hz, H-6^{I,II}, in that order). ¹³C NMR (75 MHz, C₆D₆): δ 100.05 (C-1^{II}), 97.69 (C-1^I), 78.96 (C-3^I), 78.37 (C-2^{II}), 78.13 (C-2^I), 73.56, 73.16 (2 CH₂Ph), 71.25 (C-3^{II}), 68.17 (C-5^I), 68.13 (C-1'), 68.09 (C-5^{II}), 67.03 (C-4^{II}), 65.69 (C-4^I), 51.37 (COOCH₃), 34.20 (C-5'), 29.59 (C-2'), 26.25 (C-3'), 25.19 (C-4'), 18.04 (C-6^I), 18.88 (C-6^{II}). FABMS: m/z 643.4 [M + H – 2 N +

2H]⁺, 691.4 [M + Na]⁺. Anal. Calcd for C₃₃H₄₄N₆O₉: C, 59.57; H, 6.63; N, 12.57. Found: C, 59.45; H, 6.76; N, 12.76.

3.11 5-Methoxycarbonylpentyl (4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (15)

A gentle stream of H₂S was passed through a solution of **14** (500 mg, 0.75 mmol) in 2:1 pyridine–water (5 mL) for 30 min at 40 °C. The mixture was stirred at this temperature for 16 h, when TLC (10:1:0.1 CH₂Cl₂–MeOH–conc. NH₄OH) showed that the reaction was complete. A stream of nitrogen was passed through the reaction mixture for 15 min, and the solution was co-concentrated with several co-evaporations of water to remove pyridine. After co-evaporation with toluene, to remove water, the residue was dissolved in MeOH (20 mL) and Ac₂O (1 mL) was added. After 16 h, TLC (3:2 CH₂Cl₂–acetone) showed that the reaction was complete. The mixture was concentrated and chromatography of the residue (2:1 $\rightarrow$ 1:1 CH₂Cl₂–acetone) gave **15** (390 mg, 75%), mp. 176.5–177 °C (from acetone), [α]_D +35.4 (*c* 0.8). ¹H NMR (600 MHz, ~1:1 CDCl₃–C₆D₆): δ 5.87 (d, 1 H, *J*_{4,NH} = 9.8 Hz, NH^I), 5.18 (d, 1 H, *J*_{4,NH} = 9.2 Hz, NH^{II}), 5.00 (d, 1 H, *J*_{1,2} = 1.3 Hz, H-1^{II}), 4.80 (d, 1 H, *J*_{1,2} = 2.0 Hz, H-1^I), 4.78–4.50 (4 d partially overlapped, 2 CH₂Ph), 4.25 (q, 1 H, *J* = 9.8 Hz, H-4^I), 4.00 (q, 1 H, *J* = 9.8 Hz, H-4^{II}), 3.94 (dd, *J*_{2,3} = 3.1, *J*_{3,4} = 10.4 Hz, H-3^I), 3.70 (dd, *J*_{2,3} = 3.4 Hz, H-2^{II}), 3.69 (bt, H-2^I), 3.67 (m, 2 H, H-3^{II}, 5^I), 3.60 (m, 1 H, 1'a), 3.45 (m, 1 H, H-5^{II}), 3.42 (s, 3 H, COOCH₃), 3.27 (m, 1 H, H-1'b), 2.66 (bd, 1 H, OH), 2.21–2.12 (m, 2 H, H-5'a,b), 1.80, 1.79 (2 s, 6 H, 2 COCH₃), 1.59–1.52 (m, 3 H, H-4'a,b,2'a), 1.48–1.42 (m, 1 H, H-2'b), 1.40–1.29 (m, 1 H, H-3'a), 1.27 (d, 3 H, *J*_{5,6} = 6.0 Hz, H-6^I), 1.25–1.19 (m, 1 H, H-3'b), 1.10 (d, 3 H, *J*_{5,6} = 6.2 Hz, H-6^{II}). ¹³C NMR (150 MHz, ~1:1 CDCl₃–C₆D₆): δ 99.26 (C-1^I), 97.12 (C-1^{II}), 77.52 (C-2^{II}), 77.33 (C-2^I), 76.66 (C-3^I), 72.70, 72.01 (2 CH₂Ph), 69.41 (C-3^{II}), 67.99 (C-5^{II}), 67.84 (C-5^I), 66.85 (C-1'), 53.99 (C-4^{II}), 52.68 (C-4^I), 51.22 (COOCH₃), 33.82 (C-5'), 28.62 (C-2'), 26.00 (C-3'), 24.44 (C-4'), 23.13, 23.08 (2 COCH₃), 18.09 (C-6^I), 17.94 (C-6^{II}). FABMS: *m/z* 701 [M + H]⁺, 723 [M + Na]⁺. Anal. Calcd for C₃₇H₅₂N₂O₁₁: C, 63.41; H, 7.49; N, 4.00. Found: C, 63.44; H, 7.39; N, 3.97.

3.12 5-Methoxycarbonylpentyl (4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-4,6-dideoxy- α -D-mannopyranoside (16) and 5-methoxycarbonylpentyl (4-acetamido-2,3-di-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-2-O-acetyl-4,6-dideoxy- α -D-mannopyranoside (17)

A mixture of compound **15** (140 mg) and 5% palladium-on-charcoal catalyst (140 mg) in methanol (40 mL), was stirred under hydrogen overnight at 45 °C. TLC (5:1 CHCl₃–MeOH) showed that the reaction was complete. After filtration and evaporation of the solvent, the residue was eluted from a small column of silica gel using 5:1 CHCl₃–MeOH as eluent to give, after freeze-drying and additional drying at 40 °C/133 Pa, **16** (99.5 mg, 96%), [α]_D +8.2 (*c* 1.7, H₂O). Definite signals in the ¹H NMR spectrum (600 MHz, D₂O, 50 °C) were at δ 5.18 (d, 1 H, *J*_{1,2} = 1.7 Hz, H-1^{II}), 5.08 (d, 1 H, *J*_{1,2} = 1.8 Hz, H-1^I), 4.23 (dd, 1 H, *J*_{2,3} = 3.0 Hz, H-2^I), 4.19 (t, *J* = 10.3 Hz, H-4^I), ~4.12 (dd, overlapped, H-3^I), ~4.11 (m, overlapped, H-3^{II}, 5^{II}), ~4.09 (overlapped, H-4^{II}), ~4.08 (overlapped, H-2^{II}), ~4.07 (m, H-5^I), 3.98–3.94 (m, 4 H, H-1'a, incl. s at 3.96 for COOCH₃), 3.80, 3.78 (2 t, 1 H, *J* = 6.0 Hz, H-1'b), 2.67 (t, 2 H, *J* = 7.5 Hz, H-5'a,b), 2.30, 2.29 (2 s, 6 H, 2 NHCOCH₃), 1.92–1.85 (m, 4 H, H-4'a,b,2'a,b), 1.69–1.62 (m, 2 H, H-3'a,b), 1.46 (d, 3 H, *J*_{5,6} = 6.2 Hz, H-6^I), 1.44 (d, 3 H, *J*_{5,6} = 5.8 Hz, H-6^{II}). ¹³C NMR (D₂O, 50 °C): δ 180.41 (COOCH₃), 177.67, 177.41 (2 NHCOCH₃), 105.26 (C-1^{II}), 102.75 (C-1^I), 79.99 (C-3^I), 72.68 (C-2^{II}), 72.33 (C-2^I), 71.34, 71.27 (C-3^{II}, 5^{II}), 70.96 (C-1'), 70.60 (C-5^I), 56.04 (C-4^{II}), 55.20 (COOCH₃), 55.07 (C-4^I), 36.72 (C-5'), 31.26 (C-2'), 28.07 (C-3'), 27.13 (C-4'), 25.33, 25.25 (2 COCH₃), 19.96, 19.90 (C-6^I, 6^{II}). FABMS: *m/z* 543 [M + Na]⁺. The corresponding per-O-acetyl derivative **17** showed [α]_D +58 (*c* 0.9, CHCl₃). ¹H NMR (600 MHz, CDCl₃): δ 6.09 (d, 1 H, *J*_{4,NH} = 9.5 Hz, NH^I), 5.68 (d, 1 H, *J*_{4,NH} = 10.0 Hz, NH^{II}), 5.18 (dd, 1 H, *J*_{2,3} = 3.1 Hz, H-2^I), 5.09 (dd, 1 H, *J*_{2,3} = 3.3, *J*_{3,4} = 10.9 Hz, H-3^{II}), 4.99

(d, 1 H, $J_{1,2} = 2.0$ Hz, H-1^{II}), 4.90 (dd, 1 H, H-2^{II}), 4.70 (d, 1 H, H-1^I), 4.18 (q, partially overlapped, $J = 10.1$ Hz, H-4^{II}), 4.13 (q, partially overlapped, $J = 10.9$ Hz, H-4^I), 4.07 (dd, 1 H, H-3^I), 3.88 (m, 1 H, H-5^{II}), 3.77 (m, 1 H, H-5^I), 3.69–3.66 (m, 4 H, H-1'a, incl. 3.67, s, COOCH₃), 3.42, 3.40 (2 t, 1 H, $J = 5.1$ Hz, H-1'b), 2.36 (m, 2 H, H-5'a,b), 2.23, 2.12, 2.01, 2.06, 1.96 (5 s, 15 H, 5 COCH₃), 1.67 (m, 3 H, H-2'a,4'a,b), 1.58 (m, 1 H, H-2'b), 1.49 (m, 1 H, H-3'a), 1.35 (m, 1 H, H-3'b), 1.26 (d, 3 H, $J_{5,6} = 6.2$ Hz, H-6^I), 1.23 (d, 3 H, $J_{5,6} = 6.3$ Hz, H-6^{II}). ¹³C NMR (150 MHz, CDCl₃): δ 97.97 (C-1^{II}), 97.25 (C-1^I), 73.49 (C-3^I), 70.45 (C-2^I), 69.95 (C-2^{II}), 68.84 (C-5^{II}), 67.95 (C-3^{II}), 67.63 (C-5^I), 66.86 (C-1'), 52.61 (C-4^I), 51.58 (COOCH₃), 51.34 (C-4^{II}), 33.86 (C-5'), 28.55 (C-2'), 25.88 (C-3'), 24.29 (C-4'), 23.40, 23.33 (2 NHCOCH₃), 21.20, 20.96, 20.81 (3 COCH₃), 17.92 (C-6^{II}), 17.75 (C-6^I). ESI-MS (m/z): 647.3023; calcd for [M + H]⁺ 6747.3027. Anal. Calcd for C₂₉H₄₆N₂O₁₄: C, 53.86; H, 7.17; N, 4.33. Found: C, 54.04; H, 7.26; N, 4.29.

3.13 5-Methoxycarbonylpentyl (2-O-acetyl-4-azido-3-O-benzyl-4,6-dideoxy-α-D-mannopyranosyl)-(1→3)-(4-azido-2-O-benzyl-4,6-dideoxy-α-D-mannopyranosyl)-(1→3)-4-azido-2-O-benzyl-4,6-dideoxy-α-D-mannopyranoside (18)

Reaction of **10**^{14,21} (2.2 g, 6.02 mmol) and **14** (3.125 g, 4.67 mmol) as described in the General procedure gave, after chromatography (20:1→5:1 hexane–EtOAc), the fully protected trisaccharide **18** (4.275 g, 95%), [α]_D +79.6 (c 1.2). ¹H NMR (600 MHz, C₆D₆): δ 5.87 (dd, 1 H, $J_{1,2} = 1.8$, $J_{2,3} = 3.1$ Hz, H-2^{III}), ~5.25 (d, partially overlapped, H-1^{III}), ~5.24 (d, partially overlapped, H-1^{II}), 4.81 (d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^I), 4.74–4.39 (6 d, partially overlapped, 6 H, 3 CH₂Ph), 4.22 (dd, 1 H, $J_{2,3} = 3.1$, $J_{3,4} = 9.7$ Hz, H-3^{II}), 4.13 (dd, partially overlapped, $J_{2,3} = 3.3$, $J_{3,4} = 9.2$ Hz, H-3^I), 4.12 (dd, partially overlapped, H-2^{II}), 4.10 (dd, 1 H, $J_{3,4} = 10.0$ Hz, H-3^{III}), 3.94 (m, 1 H, H-5^{III}), 3.85–3.77 (m, 3 H, H-5^{II}, 2^I, 4^{II} in that order), 3.69 (t, 1 H, $J = 9.9$ Hz, H-4^I), 3.63 (t, 1 H, $J = 9.9$ Hz, H-4^{III}), 3.59 (m, partially overlapped, H-5^I), 3.47, 3.46 (2 t, $J = 6.7$ Hz, 1 H, H-1'a), 3.36 (s, 3 H, COOCH₃), 3.12, 3.11 (2 t, 1 H, H-1'b), 2.05 (t, 2 H, $J = 7.3$ Hz, H-5'a,b), 1.65 (s, 3 H, COCH₃), 1.49–1.44 (m, 2 H, H-4'a,b), 1.36–1.29 (m, partially overlapped, H-2'a,b), 1.31 (d, partially overlapped, $J_{5,6} = 5.9$ Hz, H-6^{III}), 1.25 (d, $J_{5,6} = 6.1$ Hz, H-6^I), 1.20 (d, $J_{5,6} = 6.0$ Hz, H-6^{II}), 1.18–1.11 (m, 2 H, H-3'a,b). ¹³C NMR (150 MHz, C₆D₆): δ 100.93 (C-1^{III}), 100.04 (C-1^{II}), 97.32 (C-1^I), 80.17 (C-3^I), 79.71 (C-3^{II}), 78.34 (C-2^I), 77.80 (C-2^{II}), 76.93 (C-3^{III}), 73.02, 72.98, 72.02 (3 CH₂Ph), 68.81 (C-5^{II}) 68.54 (C-5^{III}), 68.22 (C-1'), 67.99 (C-5^I), 67.95 (C-2^{III}), 65.26 (C-4^I), 65.19 (C-4^{II}), 64.96 (C-4^{III}), 51.39 (COOCH₃), 34.18 (C-5'), 29.61 (C-2'), 26.28 (C-3'), 25.18 (C-4'), 20.73 (COCH₃), 19.09, 19.06 (2C) (C-6^{I-III}). FABMS: m/z 946 [M + H - 2N + 2H]⁺. Anal. Calcd for C₄₈H₆₁N₉O₁₃: C, 59.31; H, 6.33; N, 12.97. Found: C, 59.47; H, 6.34; N, 12.89.

3.14 5-Methoxycarbonylpentyl (4-azido-3-O-benzyl-4,6-dideoxy-α-D-mannopyranosyl)-(1→3)-(4-azido-2-O-benzyl-4,6-dideoxy-α-D-mannopyranosyl)-(1→3)-4-azido-2-O-benzyl-4,6-dideoxy-α-D-mannopyranoside (19)

Deacetylation of **18** (5.45 g, 5.6 mmol) as described for **13** gave, after chromatography and crystallization, **19** (3.75 g, 98%), mp. 37–40 °C (from isopropyl ether), [α]_D +76 (c 1.9). ¹H NMR (600 MHz, C₆D₆): δ 5.31 (d, 1 H, $J_{1,2} = 1.5$ Hz, H-1^{III}), 5.26 (d, 1 H, $J_{1,2} = 1.5$ Hz, H-1^{II}), 4.82 (d, 1 H, $J_{1,2} = 1.6$ Hz, H-1^I), 4.59–4.34 (6 d, partially overlapped, 6 H, 3 CH₂Ph), 4.24 (dd, 1 H, $J_{2,3} = 3.1$ Hz, H-2^{III}), 4.21 (dd $J_{2,3} = 3.2$, $J_{3,4} = 9.8$ Hz, H-3^{II}), ~4.14 (dd, partially overlapped, H-2^{II}), 4.13 (dd, partially overlapped, $J_{2,3} = 3.1$, $J_{3,4} = 9.9$ Hz, H-3^I), 3.90 (m, partially overlapped, H-5^{III}), 3.88 (dd, partially overlapped, $J_{3,4} = 9.8$ Hz, H-3^{II}), 3.84–3.80 (m, 2 H, H-2^I, 5^{II}), 3.77 (t, 1 H, $J = 9.9$ Hz, H-4^{II}), 3.70 (t, $J = 9.9$ Hz, H-4^I), 3.60 (m, 1 H, H-5^I), 3.51 (t, 1 H, $J = 9.9$ Hz, H-4^{III}), 3.47, 3.45 (2 t, 1 H, $J = 6.6$ Hz, H-1'a), 3.36 (s, 3 H, COOCH₃), 3.12, 3.10 (2 t, 1 H, H-1'b), 2.05 (t, 2 H, $J = 7.4$ Hz, H-5'a,b), 1.50–1.43 (m, 2 H, H-4'a,b), 1.36–1.29 (m, 5 H, H-2'a,b, 6^{III}), 1.26 (d, 3 H, $J_{5,6} = 6.1$ Hz, H-6^I), 1.20 (d, 3 H, $J_{5,6} = 6.0$ Hz, H-6^{II}), 1.17–1.12 (m, 2 H, H-3'a,b). ¹³C NMR (150 MHz, C₆D₆): δ 102.61 (C-1^{III}), 100.01 (C-1^{II}), 97.44 (C-1^I), 80.01 (C-3^I), 79.35 (C-3^{II}), 79.01 (C-3^{III}), 78.36 (C-2^I),

77.96 (C-2^{II}), 73.08, 73.00, 71.93 (3 CH₂Ph), 68.71 (C-5^{II}), 68.34 (C-5^{III}), 68.19 (C-1'), 68.05 (C-5^I), 67.83 (C-2^{III}), 65.32 (C-4^I), 65.27 (C-4^{II}), 64.59 (C-4^{III}), 51.38 (COOCH₃), 34.19 (C-5'), 29.61 (C-2'), 26.27 (C-3'), 25.19 (C-4'), 19.08, 19.05, 19.04 (C-6^{I-III}). FABMS: *m/z* 904 [M + H - 2N + 2H]⁺, 952 [M + Na]⁺. Anal. Calcd for C₄₆H₅₉N₉O₁₂: C, 59.41; H, 6.39; N, 13.55. Found: C, 59.49; H, 6.55; N, 13.55.

3.15 5-Methoxycarbonylpentyl (4-acetamido-3-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (20)

Reduction of **19** (1 g, 1.075 mmol) with H₂S followed by N-acetylation, as described for **14**, gave **20** (0.9 g, 86%). ¹H NMR (600 MHz, CD₃OD at 45 °C): δ 5.06 (d, 1 H, *J*_{1,2} = 1.8 Hz, H-1^{II}), 4.93 (d, 1 H, *J*_{1,2} = 1.8 Hz, H-1^{III}), 4.80 (d, 1 H, *J*_{1,2} = 1.8 Hz, H-1^I), 4.79–4.41 (6 d, partially overlapped, 6 H, 3 CH₂Ph), 4.18–4.13 (m, 2 H, H-4^{I,II}), 4.01–3.97 (m, 4 H, H-2^{III}, 4^{III}, 3^{I,II} in that order), 3.88 (m, 1 H, H-5^{II}), 3.82 (m, partially overlapped, H-5^{III}), 3.79 (bt, partially overlapped, H-2^I), 3.78 (bt, partially overlapped, H-2^{II}), 3.72 (m, 1 H, H-5^I), 3.69–3.63 (m, 5 H, H-1'a, 3^{III}, incl. s, 3.64, COOCH₃), 3.42, 3.41 (2 t, 1 H, *J* = 6.1 Hz, H-1'b), 2.33 (t, 2 H, *J* = 7.3 Hz, H-5'a,b), 1.97, 1.96, 1.88 (3 s, 3 H each, 3 COCH₃), 1.66–1.61 (m, partially overlapped, H-4'a,b), 1.61–1.56 (m, partially overlapped, H-2'a,b), 1.43–1.38 (m, 2 H, H-3' a,b), 1.18, 1.15, 1.13 (3 d, 3 H each, *J*_{5,6} 6.2 Hz, H-6^{I-III}, in that order). ¹³C NMR (150 MHz, CD₃OD, 45 °C): δ 103.45 (C-1^{III}), 100.58 (C-1^{II}), 98.93 (C-1^I), 79.38 (C-2^{II}), 78.85 (C-2^I), 78.11, 77.97, 77.91 (C-3^{I-III}), 74.05, 74.01, 72.07 (3 CH₂Ph), 69.74 (C-5^{II}), 69.54 (C-5^{III}), 68.96 (C-5^I), 68.59 (C-1'), 68.40 (C-2^{III}), 53.90, 53.83 (C-4^{I,II}), 53.12 (C-4^{III}), 51.99 (COOCH₃), 34.68 (C-5'), 30.09 (C-2'), 26.81 (C-3'), 25.69 (C-4'), 23.18, 22.99, 22.94 (3 NHCOCH₃), 18.54, 18.46, 18.28 (C-6^{I-III}). FABMS: *m/z* 984.5 [M + Li]⁺, 1000.50 [M + Na]⁺. FAB HRMS: *m/z* 1000.4783 (100%); calcd for C₅₂H₇₁N₃NaO₁₅, 1000.4783.

3.16 5-Methoxycarbonylpentyl (4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-4,6-dideoxy- α -D-mannopyranoside (21) and 5-methoxycarbonylpentyl (4-acetamido-2,3-di-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-2-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-2-O-acetyl-4,6-dideoxy- α -D-mannopyranoside (22)

Compound **20** (0.75 g) was treated with hydrogen, as described for **15**. Elution of the crude product from a small silica gel column (5:1 $\rightarrow$ 3:2 CH₂Cl₂-MeOH) gave compound **21** (345 mg, 64%) [α]_D +78.9 (*c* 3.7, H₂O). Structurally significant signals in the ¹H NMR spectrum (D₂O at 50 °C, 600 MHz) were at: δ 5.13 (bd, 2 H, H-1^{II,III}), 5.02 (bd, 1 H, H-1^I), 4.21 (bdd, 1 H, H-2^I), 3.93, 3.92, 3.79, 3.75 (4 t, 2 H, *J* = 6.5 Hz, H-1'a,b), 2.62 (t, 2 H, *J* = 7.4 Hz, H-5' a,b), 2.27, 2.26, 2.25 (3 bs, 12 H, 3 NHCOCH₃), 1.43–1.41 (m, H-6^{I-III}). Structurally significant signals in the ¹³C NMR spectrum (D₂O at 50 °C, 600 MHz) were at: δ 105.25, 105.13 (C-1^{II,III}), 102.75 (C-1^I), 52.11 (COOCH₃), 36.86 (C-5'), 31.31 (C-2'), 28.09 (C-3'), 27.16 (C-4'), 25.35, 25.32, 25.25 (3 NHCOCH₃), 20.03, 19.98, 19.95 (C-6^{I,III}). FABMS: *m/z* 708.5 [M + H]⁺, 730.5 [M + Na]⁺. The corresponding per-O-acetyl derivative **22** showed [α]_D +50 (*c* 1.2, CHCl₃). ¹H NMR (600 MHz, CDCl₃): δ 6.38 (d, 1 H, *J*_{4,NH} = 9.5 Hz, NH^I), 5.83 (d, 1 H, *J*_{4,NH} = 9.9 Hz, NH^{III}), 5.80 (d, 1 H, *J*_{4,NH} = 10.0 Hz, NH^{II}), 5.14 (dd, 1 H, *J*_{1,2} = 1.9 Hz, H-2^I), 5.05 (dd, 1 H, *J*_{2,3} = 2.6, *J*_{3,4} = 10.8 Hz, H-3^{III}), 5.02 (dd, 1 H, *J*_{1,2} = 2.0, *J*_{2,3} = 3.3 Hz, H-2^{II}), 4.92–4.90 (m, 3 H, H-2^{III}, 1^{III,II} in that order), 4.70 (d, 1 H, *J*_{1,2} = 1.9 Hz, H-1^I), 4.16 (t, partially overlapped, *J* = 10.0 Hz, H-4^{III}), 4.15–4.04 (m, partially overlapped, H-4^{I,II}, H-3^I in that order), 3.87 (dd, partially overlapped, H-3^{II}), 3.83 (m, partially overlapped, H-5^I), ~3.77 (m, partially overlapped, H-5^{III}), ~3.75 (m, partially overlapped, H-5^I), 3.69–3.65 (m, 4 H, H-1'a, incl. 3.68, s, COOCH₃), 3.42, 3.40 (2 t, 1 H, *J* = 5.4 Hz, H-1'b), 2.36 (m, 2 H, H-5'a,b), 2.19, 2.17, 2.14 (3 s, 9 H, 3 NHCOCH₃), 2.05, 2.02, 2.00, 1.97 (4 s, 12 H, 4 COCH₃), 1.74–1.25 (4 m, 6 H, H-4'a,b, 2'b, 3'a, 3'b in that order), 1.25, 1.23, 1.21 (3 d, 9 H, *J*_{5,6} = 6.2 Hz, H-6^{I,II,III} in that order). ¹³C NMR (150 MHz, CDCl₃): δ 98.44 (C-1^{II}), 97.85 (C-1^{III}), 97.05

(C-1^I), 73.63 (C-3^I), 72.76 (C-3^{II}), 70.53 (C-2^I), 70.37 (C-2^{II}), 69.49 (C-2^{III}), 68.82 (C-5^{III}), 68.44 (C-5^{II}), 68.05 (C-3^{III}), 67.55 (C-5^I), 68.84 (C-1'), 52.37 (C-4^I), 52.14 (C-4^{II}), 51.49 (COOCH₃), 51.02 (C-4^{III}), 33.78 (C-5'), 28.44 (C-2'), 25.76 (C-3'), 24.24 (C-4'), 23.26, 23.15, 21.12, 20.95, 20.88, 20.67 (7 COCH₃), 17.75, 17.66 (3 C, C-6^{I-III}). ESI-MS (*m/z*): 914.3589; calcd for C₃₉H₆₁N₃O₁₉K: 914.3536. Anal. Calcd for C₃₉H₆₁N₃O₁₉: C, 53.48; H, 7.02; N, 4.80. Found: C, 53.76; H, 6.98; N, 4.56.

3.17 5-Methoxycarbonylpentyl (3-O-acetyl-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-azido-3-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (23)

Reaction of **8** (1.8 g, 5 mmol) and **19** (3.75 g, 3.86 mmol) as described in General procedure gave, after chromatography (15:1 $\rightarrow$ 5:1 hexane–EtOAc), the protected tetrasaccharide **23** (4.45 g, 94%), mp. 112.5–113.5 °C (EtOH–EtOAc), [α]_D +37.2 (c 1.1). ¹H NMR (600 MHz, C₆D₆): δ 5.53 (dd, 1 H, $J_{2,3}$ = 3.1, $J_{3,4}$ = 10.1 Hz, H-3^{IV}), 5.36 (d, 1 H, $J_{1,2}$ = 1.6 Hz, H-1^{IV}), 5.32 (d, 1 H, $J_{1,2}$ = 1.8 Hz, H-1^{III}), 5.26 (d, 1 H, $J_{1,2}$ = 1.4 Hz, H-1^{II}), 4.82 (d, 1 H, $J_{1,2}$ = 1.8 Hz, H-1^I), 4.61–4.05 (8 d, partially overlapped, 4 CH₂Ph), 4.49 (bt, H-2^{III}), 4.27 (dd, partially overlapped, H-3^{II}), 4.15 (dd, 1 H, $J_{2,3}$ = 3.0, $J_{3,4}$ = 9.6 Hz, H-3^I), ~ 4.13 (m, 2 H, H-2^{II,IV}), 4.00 (dd, 1 H, $J_{2,3}$ = 2.8, $J_{3,4}$ = 9.8 Hz, H-3^{III}), 3.92–3.81 (m, partially overlapped, H-5^{IV,III,II} in that order), 3.82 (m, H-2^{I,4IV}), 4.81 (t, partially overlapped, H-4^{II}), 4.76 (t, partially overlapped, H-4^{III}), 3.74 (t, partially overlapped, H-4^I), 3.60 (m, 1 H, H-5^I), 3.48, 3.46 (2 t, 1 H, J = 6.4 Hz, H-1'a), 3.36 (s, 3 H, COOCH₃), 3.13, 3.11 (2 t, 1 H, H-1'b), 2.05 (t, 2 H, J = 7.3 Hz, H-5'a,b), 1.70 (s, 3 H, COCH₃), 1.50–1.45 (m, 2 H, H-4'a,b), 1.36–1.30 (m, 2 H, H-2'), 1.30 (d, partially overlapped, H-6^{IV}), 1.29 (d, partially overlapped, H-6^{III}), 1.25 (d, 3 H, $J_{5,6}$ = 6.2 Hz, H-6^I), 1.22 (d, 3 H, $J_{5,6}$ = 6.0 Hz, H-6^{II}), 1.17–1.14 (m, 2 H, H-3'a,b). ¹³C NMR (150 MHz, C₆D₆): δ 102.19 (C-1^{III}), 100.06 (C-1^{II}), 99.59 (C-1^{IV}), 97.36 (C-1^I), 80.11 (C-3^I), 79.43 (C-3^{III}), 79.01 (C-3^{II}), 78.53 (C-2^I), 77.90 (C-2^{II}), 75.52 (C-2^{IV}), 73.29 (C-2^{III}), 73.12, 73.09 (2 CH₂Ph), 73.01 (C-3^{IV}), 72.97, 72.78 (2 CH₂Ph), 68.98 (C-5^{III}), 68.77 (C-5^{II}), 68.71 (C-5^{IV}), 68.20 (C-1'), 68.01 (C-5^I), 65.51 (C-4^{II}), 65.34 (C-4^I), 65.10 (C-4^{III}), 63.52 (C-4^{IV}), 51.37 (COOCH₃), 34.18 (C-5'), 29.62 (C-2'), 26.28 (C-3'), 25.19 (C-4'), 20.79 (COCH₃), 19.05, 19.03, 18.89 (4 C, C-6^{I-IV}). FABMS: *m/z* 1207.6 [M + H – 2 N + 2 H]⁺, 1255 [M + Na]⁺. Anal. Calcd for C₆₁H₇₆N₁₂O₁₆: C, 59.40; H, 6.21; N, 13.63. Found: C, 59.43; H, 6.11, N, 13.54.

3.18 Methoxycarbonylpentyl (4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-azido-3-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (24)

Deacetylation of **23** (4.27 g, 3.46 mmol) as for **13**, except that the reaction was started at 50 °C, to solubilize the starting material, gave pure **24** (4.03 g, 97%), which crystallized on standing but could not be crystallized from common solvents, mp. 53–57 °C, [α]_D +10.0 (c 0.4). ¹H NMR (600 MHz, C₆D₆): δ 5.30 (bd, partially overlapped, H-1^{IV}), 5.29 (d, partially overlapped, H-1^{III}), 5.26 (d, 1 H, $J_{1,2}$ = 1.7 Hz, H-1^{II}), 4.83 (d, 1 H, $J_{1,2}$ = 1.8 Hz, H-1^I), 4.63–4.01 (8 d, partially overlapped, 4 CH₂Ph), 4.45 (bdd, 1 H, H-2^{III}), 4.25 (dd, 1 H, $J_{2,3}$ = 3.0, $J_{3,4}$ = 9.8 Hz, H-3^{II}), 4.14 (dd, 1 H, $J_{2,3}$ = 3.1, $J_{3,4}$ = 10.0 Hz, H-3^I), 4.11 (dd, 1 H, $J_{2,3}$ = 3.0 Hz, H-2^{II}), 4.05 (dd, 1 H, $J_{2,3}$ = 3.6, $J_{3,4}$ = 9.9 Hz, H-3^{IV}), 3.97 (dd, 1 H, $J_{2,3}$ = 3.5, $J_{3,4}$ = 9.7 Hz, H-3^{III}), 3.86–3.81 (m, partially overlapped, H-5^{II,III}), 3.82 (dd, partially overlapped, H-2^I), 3.80 (t, partially overlapped, J = 9.8 Hz, H-4^{II}), ~3.74 (m, partially overlapped, H-5^{IV}), 3.72 (m, partially overlapped, H-4^{I,2IV}), 3.62–3.56 (m, 2 H, H-5^{I,4III}), 3.49, 3.47 (2 t, 1 H, J = 6.5 Hz, H-1'a), 3.37 (s, partially overlapped, COOCH₃), 3.35 (t, partially overlapped, J = 10.0 Hz, H-4^{IV}), 3.15, 3.13 (2 t, 1 H, H-1'b), 2.06 (t, 2 H, J = 7.4 Hz, H-5'a,b), 1.51–1.46 (m, 2 H, H-4'a,b), 1.38–1.32 (m, partially overlapped, H-2'a,b), 1.31–1.21 (4 d, partially overlapped, H-6^{I-IV}),

1.20–1.13 (m, 2 H, H-3'a,b). ^{13}C NMR (150 MHz, C_6D_6): δ 102.22 (C-1^{III}), 100.10 (C-1^{II}), 98.96 (C-1^{IV}), 97.33 (C-1^I), 80.16 (C-3^I), 79.20 (C-3^{III}), 78.86 (C-3^{II}), 78.49 (C-2^I), 77.88 (C-2^{II}), 77.41 (C-2^{IV}), 73.11, 73.06, 72.81, 72.66 (4 CH_2Ph), 72.97 (C-2^{III}), 71.10 (C-3^{IV}), 68.79, 68.77 (C-5^{II,III}), 68.23 (C-1'), 68.21 (C-5^{IV}), 68.00 (C-5^I), 67.03 (C-4^{IV}), 65.67 (C-4^{II}), 65.33 (C-4^I), 65.10 (C-4^{III}), 51.43 (COOCH_3), 34.20 (C-5'), 29.61 (C-2'), 26.28 (C-3'), 25.19 (C-2'), 19.01, 18.95, 18.75 (4 C, C-6^{I-IV}). FABMS: m/z 1165.6 [$\text{M} + \text{H} - 2\text{N} + 2\text{H}$]⁺. Anal. Calcd for $\text{C}_{59}\text{H}_{74}\text{N}_{12}\text{O}_{15}$: C, 59.48; H, 6.26; N, 14.11. Found: C, 59.50; H, 6.27; N, 13.83.

3.19 5-Methoxycarbonylpentyl (4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-acetamido-3-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (25)

Treatment of **24** (1.42 g, 1.19 mmol) as for compound **19** but in pyridine and water (3:1), to assist solubility of the starting material, gave the corresponding, intermediate *tetrakis*-amine (1 g). FABMS: m/z 1087.62 [$\text{M} + \text{H}$]⁺, 1109.61 [$\text{M} + \text{Na}$]⁺.

A solution of the foregoing amine was *N*-acetylated, as described for preparation of **15**, to give after chromatography **25** (1.05 g, 70% from **24**), $[\alpha]_{\text{D}} +30.0$ (*c* 0.2). Structurally significant ^1H NMR (600 MHz, C_6D_6) signals were at: δ 7.62, 6.73, 5.86, 5.48 (4 bs, $\text{NH}^{\text{I-IV}}$), 5.21, 5.10, 5.07 (3 bs, H-1^{II-IV}), 4.80 (bs, H-1^I), 4.37–4.28 (m, 4 H, H-4^{I-IV}), 3.60–3.58, 3.24–3.22 (2 m, 2 H, H-1'a,b), 3.38 (s, 3 H, COOCH_3), 2.12–2.09 (m, 2 H, H-5'a,b), 2.00, 1.99, 1.87, 1.43 (4 s, 4 NHCOCH_3), 1.46, 1.31, 1.24, 1.23 (4 d, H-6^{I-IV}). The spectrum taken in CD_3OD showed peaks at: δ 5.08, 5.01, 4.96 (3 d, 1 H each, H-1^{II-IV}), 4.80 (d, 1 H, $J_{1,2} = 1.9$ Hz, H-1^I), 4.82–4.36 (8 d, 1 H, each, 4 CH_2Ph), 4.15 (bt, partially overlapped, H-4^I), 3.78 (bdd, 1 H, H-2^I), 3.64 (s, partially overlapped, COOCH_3), 3.42, 3.40 (2 t, 1 H, $J = 6.2$ Hz, H-1' b), 2.43 (t, 2 H, $J = 7.3$ Hz, H-5'a,b), 1.99, 1.98, 1.96, 1.93 (4 s, 3 H each, 4 NHCOCH_3), 1.18, 1.17, 1.12, 1.10 (4 d, 12 H, $J_{5,6} \sim 6.3$ Hz, H-6^{I-IV}). Structurally significant ^{13}C NMR (150 MHz, C_6D_6) signals were at: δ 101.20, 99.40, 97.84 (br, C-1^{II-IV}), 96.89 (br, C-1^I), 51.03 (COOCH_3), 23.27, 23.16, 23.09, 22.96 (NHCOCH_3). The spectrum taken in CD_3OD showed peaks at: δ 102.19, 100.66 (3 C) (C-1^{II-IV}), 98.94 (C-1^I), 74.25, 74.00, 73.92, 72.75 (4 CH_2Ph), 68.57 (C-1'), 52.06 (COOCH_3), 23.30, 23.25, 22.91, 22.88 (4 NHCOCH_3), 18.68, 18.67, 18.57, 18.26 (C-6^{I-IV}). FABMS: m/z 1278 [$\text{M} + \text{Na}$]⁺.

3.20 5-Methoxycarbonylpentyl (4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-4,6-dideoxy- α -D-mannopyranoside (26) and 5-methoxycarbonylpentyl (4-acetamido-2,3-di-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-acetamido-3-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-2-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-2-O-acetyl-4,6-dideoxy- α -D-mannopyranoside (27)

Hydrogenolysis of **25** (960 mg) and processing as described for **16**, gave the deprotected, amorphous tetrasaccharide **26** in virtually theoretical yield, $[\alpha]_{\text{D}} +62.4$ (*c* 6.6, H_2O). ^1H NMR (600 MHz, D_2O at 50 °C): δ 5.27 (d, 1 H, $J_{1,2} = 1.6$ Hz, H-1^{III}), 5.20, d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^{II}), 5.15 (d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^{IV}), 5.05 (d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^I), 4.33 (bdd, 1 H, H-2^{II}), 4.25 (bt, 1 H, H-2^I), ~4.23 (m, partially overlapped, H-3^{III}), ~4.19 (m, partially overlapped, H-3^{II}), 4.12 (m, partially overlapped, H-3^I), ~4.09 (m, partially overlapped, H-2^{IV}), 4.03 (bdd, 1 H, H-2^{III}), 3.96 (m, 4 H, H-1'a, incl s, 3.96 COOCH_3), 3.80, 3.78 (2 t, 1 H, $J = 6.1$ Hz, H-1'b), 2.66 (t, 2 H, $J = 7.4$ Hz, H-5'a,b), 2.31, 2.30, 2.29, 2.28 (4 s, 3 H each, 4 NHCOCH_3), 1.92–1.85 (m, 4 H, H-2'a,b4'a,b), 1.69–1.62 (m, 2 H, H-3'a,b), 1.46–1.45 (m, 12 H, H-6^{I-IV}). ^{13}C NMR (150 MHz, D_2O at 50 °C): δ 105.47 (C-1^{II}), 105.21 (C-1^{IV}), 103.90 (C-1^{III}), 102.72 (C-1^I), 81.60 (C-2^{III}), 80.52 (C-3^I), 80.02 (C-3^{II}), 72.58 (C-2^{IV}), 72.39

(C-2^I), 72.20 (C-2^{II}), 70.98 (C-1'), 52.08 (COOCH₃), 36.70 (C-5'), 31.23 (C-2'), 28.04 (C-3'), 27.10 (C-4'), 25.43, 25.34, 25.30, 25.27 (4 NHCOCH₃), 20.20, 20.05, 19.90, 19.86 (C-6^{I-IV}). FABMS: m/z 917.5 [M + Na]⁺. The corresponding per-O-acetyl derivative **27** showed [α]_D +67, c 1.1, CHCl₃. ¹H NMR (600 MHz, CDCl₃): δ 6.98 (d, 1 H, $J_{4,NH}$ = 9.3 Hz, NH^{IV}), 6.38 (d, 1 H, $J_{4,NH}$ = 9.8 Hz, NH^I), 5.82 (bd, 2 H, NH^{II,III}), 5.16–5.13 (m, 3 H, H-2^{I,2IV,3IV}, in that order), 5.06 (dd, 1 H, $J_{2,3}$ = 3.2 Hz, $J_{3,4}$ = 8.7 Hz, H-3^{III}), 4.95 (bdd, 1 H, H-2^{II}), 4.90 (d, 1 H, $J_{1,2}$ = 2.0 Hz, H-1^{II}), 4.88 (d, 1 H, $J_{1,2}$ = 2.8 Hz, H-1^{III}), 4.86 (bd, 1 H, $J_{1,2}$ ~ 1 Hz, H-1^{IV}), 4.71 (d, 1 H, $J_{1,2}$ = 1.7 Hz, H-1^I), 4.20 (bq, 1 H, H-4^{IV}), 4.13 (bq, 1 H, H-4^I), 4.04–3.99 (m, 3 H, H-3^{II,4III,3I}, in that order), 3.94–3.81 (m, 4 H, H-4^{II,5II,2III,5IV}, in that order), 3.75 (m, partially overlapped, H-5^I), 3.73–3.65 (m, 5 H, H-5^{III,1'a}, incl. 3.68, s, COOCH₃), 3.42, 3.40 (2 t, 1 H, J = 5.2 Hz, H-1'b), 2.36 (t, 2 H, J = 7.0 Hz, H-5'), 2.19, 2.14, 2.13, 2.08, 2.07, 2.03, 2.01, 1.98, 1.97 (9 s, 3 H each, 9 COCH₃), 1.71–1.61 (m, 3 H, H-4'a,b,2'a), 1.60–1.55 (m, H-2'b), 1.45, 1.38 (2 m, 2 H, H-3'a,b), 1.29, 1.25, 1.23, 1.20 (4 d, $J_{5,6}$ = 1.2 Hz, H-6^{IV,I,III,II} in that order). ¹³C NMR (CDCl₃, 150 MHz): δ 99.55 (C-1^{III}), 98.55 (C-1^{II}), 97.85 (C-1^{IV}), 97.06 (C-1^I), 74.59 (C-3^I), 74.21 (C-2^{III}), 72.04 (C-3^{II}), 70.95 (C-2^{II}), 69.71 (C-3^{III}), 70.55, 68.88 (C-2^{I,IV}), 68.81 (C-3^{IV}), 68.56 (C-5^{III}), 68.50 (C-5^{IV}), 68.19 (C-5^{II}), 67.46 (C-5^I), 66.81 (C-1'), 52.74 (C-4^{II}), 52.30 (2 C, C-4^{I,III}), 51.58 (COOCH₃), 50.88 (C-4^{IV}), 33.80 (C-5'), 28.48 (C-2'), 25.77 (C-3'), 24.21 (C-4'), 23.49, 23.36, 23.26, 23.16 (4 NHCOCH₃), 21.14, 21.01, 20.91, 20.79, 20.78 (5 COCH₃), 18.07, 17.78, 17.74, 17.73 (C-6^{I-IV}). ESI-MS (m/z): 1105.4944 [M + H]⁺; calcd for C₄₉H₇₇N₄O₂₄: 1105.4928. Anal. Calcd for C₄₉H₇₆N₄O₂₄: C, 53.25; H, 6.93; N, 5.07. Found: C, 53.07; H, 6.97; N, 5.00.

3.21 5-Methoxycarbonylpentyl (3-O-acetyl-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-azido-3-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (28**)**

Condensation of the glycosyl donor **8** (1 g, 2.73 mmol) and acceptor **24** (2.61 g, 2.19 mmol), performed as described in General procedure, afforded pure (TLC, NMR) **28** (2.37 g, 73%), [α]_D +49.8. ¹H NMR (600 MHz, C₆D₆): δ 5.55 (dd, 1 H, $J_{2,3}$ = 3.3, $J_{3,4}$ = 10.1 Hz, H-3^V), 5.39 (d, 1 H, $J_{1,2}$ = 1.6 Hz, H-1^{III}), 5.36 (d, 1 H, $J_{1,2}$ = 1.6 Hz, H-1^{IV}), 5.28 (d, 1 H, $J_{1,2}$ = 1.6 Hz, H-1^V), 5.24 (d, 1 H, $J_{1,2}$ = 1.6 Hz, H-1^{II}), 4.81 (d, 1 H, $J_{1,2}$ = 1.6 Hz, H-1^I), 4.61–4.36 (m, 11 H, 5 CH₂Ph, incl. bdd, 4.46, H-2^{III}), 4.27 (dd, 1 H, $J_{2,3}$ = 3.1, $J_{3,4}$ = 9.9 Hz, H-3^{II}), 4.22 (dd, $J_{2,3}$ = 3.0, $J_{3,4}$ = 10.1 Hz, H-3^{IV}), 4.19 (dd, H-2^V), 4.13 (dd, partially overlapped, $J_{2,3}$ = 3.2, $J_{3,4}$ = 9.9 Hz, H-3^I), ~4.11 (dd, partially overlapped, H-2^{II}), 4.00 (dd, 1 H, $J_{2,3}$ = 2.9, $J_{3,4}$ = 9.9 Hz, H-3^{III}), 3.89 (dd, partially overlapped, H-2^{IV}), 3.87 (m, partially overlapped, H-5^{III,II,IV}, in that order), ~3.82 (m, partially overlapped, H-2^I), 3.80 (t, partially overlapped, H-4^{II}), 3.79 (t, partially overlapped, H-4^V), ~3.73 (m, partially overlapped, H-5^V), 3.71 (t, partially overlapped, H-4^{IV}), 3.69 (t, partially overlapped, H-4^I), 3.66 (t, partially overlapped, H-4^{III}), 3.58 (m, partially overlapped, H-5^I), 3.48, 3.46 (2 t, 1 H, J = 6.5 Hz, H-1'a), 3.37 (s, 3 H, COOCH₃), 3.14, 3.12 (2 t, 1 H, H-1'b), 2.05 (t, 2 H, J = 7.3 Hz, H-5'a,b), 1.72 (s, 3 H, COCH₃), 1.50–1.45 (m, 2 H, H-4'a,b), 1.37–1.31 (m, partially overlapped, H-2'a,b, incl. 1.33, d, $J_{5,6}$ = 6.2 Hz, H-6^{III}), 1.28 (d, $J_{5,6}$ = 6.1 Hz, H-6^{IV}), 1.24 (d, partially overlapped, $J_{5,6}$ = 6.2 Hz, H-6^I), 1.23, (d, partially overlapped, H-6^V), 1.22 (d, partially overlapped, H-6^{II}). ¹³C NMR (150 MHz, C₆D₆): δ 102.21 (C-1^{III}), 100.26 (C-1^V), 100.08 (C-1^{II}), 99.60 (C-1^{IV}), 97.38 (C-1^I), 80.18 (C-3^I), 79.04 (C-3^{III}), 78.96 (C-3^{II}), 78.47 (C-2^I), 77.87 (C-2^{II}), 77.45 (C-2^{IV}), 77.43 (C-3^{IV}), 76.21 (C-2^V), 73.85 (C-2^{III}), 73.73, 73.10, 73.07 (3 CH₂Ph), 72.94 (2 C, CH₂Ph, C-3^V), 72.67 (CH₂Ph), 69.27 (C-5^{IV}), 68.82, 68.78 (C-5^{II,III}), 68.70 (C-5^V), 68.24 (C-1'), 68.02 (C-5^I), 65.62 (C-4^{II}), 65.56 (C-4^{III}), 65.37, 65.34 (C-4^{I,IV}), 63.46 (C-4^V), 51.38 (COOCH₃), 34.19 (C-5'), 29.62 (C-2'), 26.30 (C-3'), 25.20 (C-4'), 20.79 (COCH₃), 19.09 (C-6^{III}), 19.05 (C-6^{IV}), 19.03, 18.97 (C-6^{I,IV}), 18.75 (C-6^{II}). FABMS: m/z 1468.7 [M + H – 2 N + 2 H]⁺, 1516.6 [M + Na]⁺. Anal. Calcd for C₇₄H₉₁N₁₅O₁₉: C, 59.47; H, 6.14; N, 14.06. Found: C, 59.30; H, 6.21; N, 13.93.

3.22 5-Methoxycarbonylpentyl (4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-azido-3-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-azido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (29)

Deacetylation of **28** (2.25 g, 1.505 mmol) as described for **12**, except that 1:2 MeOH–toluene mixture was used as solvent, gave **29** (2.05 g, 94%), $[\alpha]_D +69.2$ (c 2.4). ^1H NMR (600 MHz, C_6D_6): δ 5.37 (d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^{III}), 5.36 (d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^{IV}), 5.24 (d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^{II}), 5.20 (d, 1 H, $J_{1,2} = 1.3$ Hz, H-1^V), 4.81 (d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^I), 4.60–4.21 (10 d, partially overlapped, 5 CH_2Ph), 4.46 (bt, 1 H, H-2^{III}), 4.27 (dd, 1 H, $J_{2,3} = 3.1$, $J_{3,4} = 9.9$ Hz, H-3^{IV}), 4.18 (dd, 1 H, $J_{2,3} = 3.0$, $J_{3,4} = 10.2$ Hz, H-3^{IV}), 4.12 (dd, 1 H, $J_{2,3} = 3.2$, $J_{3,4} = 9.9$ Hz, H-3^I), 4.10 (dd, 1 H, H-2^{II}), 4.02 (dd, 1 H, $J_{2,3} = 3.6$, $J_{3,4} = 9.8$ Hz, H-3^V), 3.99 (dd, 1 H, $J_{3,4} = 9.9$ Hz, H-3^{III}), 3.88–3.82 (m, 5 H, H-2^{IV}, 2^V, 5^{III}, 5^{IV}, 5^{II}, in that order), 3.81 (bt, 1 H, H-2^I), 3.80 (t, 1 H, $J = 10.0$ Hz, H-4^{II}), 3.74 (t, 1 H, $J = 10.0$ Hz, H-4^{IV}), 3.68 (t, partially overlapped, $J = 10.0$ Hz, H-4^I), 3.66 (t, partially overlapped, $J = 10.0$ Hz, H-4^{III}), 3.59 (m, 2 H, H-5^V, 5^I, in that order), 3.48, 3.46 (2 t, 1H, $J = 6.6$ Hz, H-1'a), 3.36 (s, 3 H, COOCH_3), 3.30 (t, 1 H, $J = 9.9$ Hz, H-4^V), 3.14, 3.12 (2 t, 1 H, H-1'b), 2.05 (t, 2 H, $J = 7.2$ Hz, H-5'a,b), 1.50–1.45 (m, 2 H, H-4'a,b), 1.37–1.31 (m, partially overlapped, H-2'a,b), 1.31 (d, partially overlapped, $J_{5,6} = 6.2$ Hz, H-6^{III}), 1.30 (d, 3 H, $J_{5,6} = 6.2$ Hz, H-6^{IV}), 1.23 (d, 3 H, $J_{5,6} = 6.2$ Hz, H-6^I), 1.22 (d, 3 H, $J_{5,6} = 6.2$ Hz, H-6^V), 1.21 (d, 3 H, $J_{5,6} = 6.1$ Hz, H-6^{II}), 1.18–1.13 (m, 2 H, H-3'a,b). ^{13}C NMR (C_6D_6 , 150 MHz): δ 102.19 (C-1^{III}), 100.04 (C-1^{II}), 99.86 (C-1^V), 99.34 (C-1^{IV}), 97.34 (C-1^I), 80.34 (C-3^I), 79.05 (C-3^{III}), 78.97 (C-3^{II}), 78.44 (C-2^I), 78.30 (C-2^V), 77.92 (C-3^{IV}), 77.83 (C-2^{II}), 77.38 (C-2^{IV}), 73.83 (C-2^{III}), 73.54, 73.07, 73.02, 72.68, 72.62 (5 CH_2Ph), 71.28 (C-3^V), 69.17 (C-5^{IV}), 68.83, 68.76 (C-5^{II,III}), 68.25 (C-1'), 68.10 (C-5^V), 67.99 (C-5^I), 66.86 (C-4^V), 65.58 (C-4^{II}), 65.52 (C-4^{IV}), 65.50 (C-4^{III}), 65.30 (C-4^I), 51.41 (COOCH_3), 34.19 (C-5'), 29.62 (C-2'), 26.29 (C-3'), 25.19 (C-4'), 19.07, 19.04, 19.02 (2 C), 18.78 (C-6^{I-V}). FABMS: m/z 1426.6 $[\text{M} + \text{H} - 2\text{N} + 2\text{H}]^+$, 1474.5 $[\text{M} + \text{Na}]^+$. Anal. Calcd for $\text{C}_{72}\text{H}_{89}\text{N}_{15}\text{O}_{18}$: C, 59.53; H, 6.18; N 14.46. Found: C, 59.56; H, 6.25; N, 14.57.

3.23 5-Methoxycarbonylpentyl (4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-acetamido-3-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-2-O-benzyl-4,6-dideoxy- α -D-mannopyranoside (30)

Reduction of **29** (1.935 g, 1.33 mmol) in 3:1 pyridine- H_2O was performed as described for **24**. After work-up and chromatography (EtOAc–methanol 5:1 to 3:1), the intermediate *pentakis*-amine {(m/z 1322.67 $[\text{M} + \text{H}]^+$) was N-acetylated, as described above for similar conversions, and chromatography (CH_2Cl_2 –acetone 1:1 $\rightarrow$ 2:3) gave **30** (1.5 g, 74%), $[\alpha]_D +31.2$ (c 1.8). FABMS: m/z 1532.8 $[\text{M} + \text{H}]^+$, 1554.8 $[\text{M} + \text{Na}]^+$. Structurally significant resonances in the ^1H NMR (600 MHz, CD_3OD at 45 $^\circ\text{C}$) were at: δ 5.15, 5.08, 5.07, 5.02 (4 d, 1 H each, $J_{1,2} \sim 1.6$ Hz, H-1^{II-V}), 4.79 (d, 1 H, $J_{1,2} = 1.6$ Hz, H-1^I), 4.80–4.41 (10 d, partially overlapped, 5 CH_2Ph), 3.64 (s, 3 H, COOCH_3), 2.33 (t, 2 H, $J = 7.5$ Hz, H-5'), 1.98, 1.97, 1.95, 1.92, 1.89 (5 s, 3 H each, 5 NHCOCH_3), 1.19, 1.18, 1.14, 1.30, 1.12 (5 d, partially overlapped, H-6^{I-V}). Structurally significant resonances in the ^{13}C NMR (150 MHz, CD_3OD at 45 $^\circ\text{C}$) were at: δ 102.20, 100.92, 100.28, 100.16 (C-1^{II-V}), 99.12 (C-1^I), 74.28, 74.15, 74.02, 73.96, 73.19 (5 CH_2Ph), 68.78 (C-1'), 52.14 (COOCH_3), 23.50, 23.44, 23.21, 23.06, 23.03 (5 NHCOCH_3), 18.90, 18.77, 18.73, 18.72, 18.46 (C-6^{I-V}).

3.24 5-Methoxycarbonylpentyl (4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-acetamido-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-4,6-dideoxy- α -D-mannopyranoside (31) and 5-methoxycarbonylpentyl (4-acetamido-2,3-di-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-2-O-

acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-(4-acetamido-3-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-(4-acetamido-2-O-acetyl-4,6-dideoxy- α -D-mannopyranosyl)-(1 $\rightarrow$ 3)-4-acetamido-2-O-acetyl-4,6-dideoxy- α -D-mannopyranoside (32)

Hydrogenolysis of **30** (1.4 g, 0.91 mmol), performed as described for **25** gave, after freeze-drying, the deprotected pentasaccharide **31** in virtually theoretical yield, $[\alpha]_D +79.2$ (*c* 5.1, H₂O). Structurally significant resonances in the ¹H NMR spectrum (600 MHz, D₂O at 50 °C) were at 5.26 (d, 1 H, $J_{1,2} = 1.4$ Hz, H-1^{III}), 5.22, 5.19, 5.15 (3 d, $J_{1,2} \sim 1.6$ Hz, H-1^{II,IV,V}), 5.05 (d, 1 H, $J_{1,2} = 1.5$ Hz, H-1^I), 4.24 (dd, 1 H, $J_{2,3} = 3.1$ Hz, H-2^I), 4.04 (d, 1 H, $J_{2,3} = 3.0$ Hz, H-2^{III}), 3.95 (m, 4 H, H-1'a, incl s, COOCH₃), 3.80, 3.78 (2 t, 1 H, H-1'b), 2.66 (t, 2 H, $J = 7.6$ Hz, H-5'a,b), 2.31, 2.30, 2.28 (3 s, 15 H, 5 NHCOCH₃), 1.91–1.84 (m, 4 H, H-2'a,b,4'a,b), 1.68–1.60 (m, 2 H, H-3'a,b), 1.48–1.44 (5 d, partially overlapped, H-6^{I–V}). ¹³C NMR (150 MHz, D₂O at 50 °C): δ 105.26, 105.22, 105.07 (C-1^{II,IV,V}), 103.84 (C-1^{III}), 102.71 (C-1^I), 81.48 (C-2^{III}), 80.56, 80.25, 79.67 (C-3^{I,II,IV}), 70.99 (C-1'), 52.06 (COOCH₃), 36.69 (C-5'), 31.21 (C-2'), 28.01 (C-3'), 25.08 (C-4'), 25.41, 25.29, 25.28, 25.34, 25.22 (5 NHCOCH₃), 20.13, 20.04, 19.94, 19.87, 19.83 (C-6^{I–V}). FAB/MS: m/z 1082.6 [M + H]⁺, 1104.6 [M + Na]⁺. The corresponding per-O-acetyl derivative **32** showed $[\alpha]_D +57$ (*c* 1.1, CHCl₃). ESI-MS (m/z): 1351.6146 [M + NH₄]⁺, calcd for C₅₉H₉₅N₆O₂₉: 1351.6143. ¹H NMR (CDCl₃, 600 MHz): δ 7.33 (bd, 1H, NH^{IV}), 6.39 (d, 1 H, $J_{4,NH} = 10.1$ Hz, NH^I), 5.98 (bs, 1 H, NH^{II}), 5.86 (bd, 1 H, NH^{III}), 5.78 (d, 1 H, $J_{4,NH} = 9.9$ Hz NH^V), 5.18 (bdd, 1 H, H-2^{IV}), 5.15 (dd, 1 H, $J_{1,2} = 1.9$, $J_{2,3} = 3.2$ Hz, H-2^I), 5.07 (dd, partially overlapped, H-3^V), ~5.07 (d, partially overlapped, H-1^V), ~5.06 (dd, partially overlapped, H-3^{III}), 4.95 (dd, 1 H, $J_{1,2} = 2.0$, $J_{2,3} = 3.1$ Hz, H-2^V), 4.92 (bt, 1 H, H-2^{II}), 4.90 (d, 1 H, $J_{1,2} = 2.0$ Hz, H-1^{II}), 4.84 (d, 1 H, $J_{1,2} = 1.7$ Hz, H-1^{IV}), 4.83 (bd, 1 H, $J_{1,2} \sim 3$ Hz, H-1^{III}), 4.71 (d, 1 H, $J_{1,2} = 1.9$ Hz, H-1^I), 4.16, t, partially overlapped, $J \sim 10.0$ Hz, H-4^V), 4.14 (t, partially overlapped, H-4^{IV}), 4.12 (t, partially overlapped, $J = 10.4$ Hz, H-4^I), 4.04–3.97 (m, 4 H, H-3^{IV}, 3^{II}, 4^{III}, 3^I, in that order), 3.96–3.89 (m, 3 H, H-5^V, 4^{II}, 5^{II}), 3.86 (bt, 1 H, H-2^{III}), 3.80 (m, 1 H, H-5^{IV}), 3.74 (m, 1 H, H-5^I), 3.70–3.65 (m, 5 H, H-5^{III}, 1'a, incl 3.68, s COOCH₃), 3.41, 3.40 (2 t, 1 H, $J = 4.9$ Hz, H-1'b), 2.37 (t, 2 H, $J = 6.9$ Hz, H-5'a,b), 2.22–1.97 (10 s, 33 H, 11COCH₃), 1.71–1.63 (m, 3 H, H-2'a,4'a,b), 1.61–1.54 (m, 1 H, H-2'b), 1.53–1.46 (m, 1 H, H-3'a), 1.37–1.30 (m, 1 H, H-3'b), 1.28–1.20 (6 d, 15 H, partially overlapped, $J_{5,6} \sim 6.2$ Hz, H-6^{I–V}). ¹³C NMR (CDCl₃, 150 MHz): δ 99.60 (C-1^{III}), 98.58 (C-1^{II}), 97.81 (b, C-1^{IV}), 97.31 (C-1^V), 97.02 (C-1^I), 74.77 (b, C-3^I), 73.64 (b, C-2^{III}), 72.05 (b, C-3^{II}), 71.47 (b, C-3^{IV}), 71.03 (C-2^{II}), 70.59 (C-2^I), 69.96 (C-3^{III}), 69.87 (C-2^{IV}), 69.57 (C-2^V), 68.57 (C-5^V), 68.48 (C-5^{III}), 68.39 (C-5^{IV}), 68.09 (C-5^{II}), 68.00 (C-3^V), 67.45 (C-5^I), 66.72 (C-1'), 52.79 (C-4^{II}), 52.40 (C-4^{III}), 52.26 (2 C, C-4^{I,IV}), 51.56 (COCH₃), 51.19 (C-4^V), 33.79 (C-5'), 28.47 (C-2'), 25.72 (C-3'), 24.16 (C-4'), 23.46, 23.37, 23.33 (2 C), 23.13 (5 NHCOCH₃), 21.07, 21.04, 20.99, 20.93, 20.73 (5 COCH₃), 18.08, 17.83, 17.76, 17.70, 17.64 (C-6^{I–V}). Anal. Calcd for C₅₉H₉₁N₅O₂₉: C, 53.11; H, 6.87; N, 5.25. Found: C, 52.99; H, 6.99; N, 5.01.

Acknowledgment

This research was supported by the Intramural Research Program of the NIH, NIDDK.

References

1. Badger JL, Stins MF, Kim KS. Infect. Immun 1999;67:4208–4215. [PubMed: 10417193]
2. Lipinski T, Zatonksy GV, Kocharova NA, Jaquinod M, Forest E, Shashkov AS, Gamian A, Knirel YA. Eur. J. Biochem 2002;269:93–99. [PubMed: 11784302]
3. Perry MB, Bundle DR. Infect. Immun 1990;58:1391–1395. [PubMed: 1691146]
4. Taylor RK, Kirn TJ, Kovac P, Wade WF. Res. Adv. Infect. Dis 2003;1:1–11.
5. Chernyak A, Kondo S, Wade TK, Meeks MD, Alzari PM, Fournier J-M, Taylor RK, Kováč P, Wade WF. J. Infect. Dis 2002;185:950–962. [PubMed: 11920320]

6. Saksena R, Ma X, Kováč P. Carbohydr. Res 2003;338:2591–2603. [PubMed: 14670719]
7. Ma X, Saksena R, Chernyak A, Kováč P. Org. Biomol. Chem 2003;1:775–784. [PubMed: 12929359]
8. Adamo R, Kováč P. Eur. J. Org. Chem 2006:2803–2809.
9. Adamo R, Kováč P. Eur. J. Org. Chem 2007:988–2000.
10. Lei, P-s; Ogawa, Y.; Kováč, P. Carbohydr. Res 1995;279:117–131. [PubMed: 8593618]
11. Lei, P-s; Ogawa, Y.; Kováč, P. Carbohydr. Res 1996;281:47–60. [PubMed: 8839176]
12. Ogawa Y, Lei P-s, Kováč P. Carbohydr. Res 1996;293:173–194. [PubMed: 8938375]
13. Ogawa Y, Lei P-s, Kovac P. Carbohydr. Res 1996;288:85–98. [PubMed: 8765728]
14. Zhang J, Kováč P. Carbohydr. Res 1997;300:329–339. [PubMed: 9210300]
15. Kováč, P. Studies Toward a Rationally Designed Conjugate Vaccine for Cholera Using Synthetic Carbohydrate Antigens. Bewley, C., editor. London: Royal Society of Chemistry; 2006. p. 175-220.
16. Hermanson, GT. Book Bioconjugate Techniques. New York: Academic Press; 1996. Bioconjugate Techniques.
17. Lee, YC.; Lee, RT. Book Neoglycoconjugates: Preparation and Application. New York: Academic Press; 1994. Neoglycoconjugates: Preparation and Application.
18. Chernyak A, Karavanov A, Ogawa Y, Kováč P. Carbohydr. Res 2001;330:479–486. [PubMed: 11269399]
19. Gotoh M, Kováč P. J. Carbohydr. Chem 1994;13:1193–1213.
20. Eis MJ, Ganem B. Carbohydr. Res 1988;176:316–323. [PubMed: 3138026]
21. Bundle DR, Gerken M, Peters T. Carbohydr. Res 1988;174:239–251. [PubMed: 2454158]
22. Peters T, Bundle DR. Can. J. Chem 1989;67:497–502.
23. Nashed MA. Carbohydr. Res 1978;60:200–205.
24. Solladie G, Ziani-Cherif C. J. Org. Chem 1993;58:2181–2185.
25. Banoub J, Bundle D. Can. J. Chem 1979;57:2085–2090.
26. Peltier JM, Smith RW, MacLean DB, Szarek WA. Carbohydr. Res 1990;207:1–10. [PubMed: 2076509]
27. Pavliak V, Kováč P, Glaudemans CPJ. Carbohydr. Res 1991;229:103–116. [PubMed: 1381283]
28. Adachi T, Yamada Y, Inoue I, Saneyoshi M. Synthesis 1977:45–46.

Scheme 1.

Scheme 2.

Scheme 3.

Scheme 4.